Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.
Market Dynamics
Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy’s Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.
Key features of the study:
- This report provides in-depth analysis of childhood absence epilepsy treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2018–2026), considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
- Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
- The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market
Detailed Segmentation:
- Global Childhood Absence Epilepsy Treatment Market, By Drug:
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- Global Childhood Absence Epilepsy Treatment Market, By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- Global Childhood Absence Epilepsy Treatment Market, By Region:
- North America
- By Drug
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- By Country:
- Europe
- By Drug
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Drug
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Drug
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug
- Ethosuximide
- Valproate
- Lamotrigine
- Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
- By Disease Type:
- Typical Absence Seizures
- Atypical Absence Seizures
- By Country:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Cavion, Inc. *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Pfizer, Inc.
- GlaxoSmithKline Plc
- Insys Therapeutics, Inc.
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
